Helmut Hanenberg1,2,3, Paul R Andreassen4,5, Jung-Young Park4, Elizabeth L Virts1, Anna Jankowska1, Constanze Wiek2, Mohamed Othman6, Sujata C Chakraborty7, Gail H Vance7, Fowzan S Alkuraya8,9. 1. Wells Center for Pediatric Research, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN 46202. 2. Department of Otorhinolaryngology & Head/Neck Surgery, Heinrich Heine University 40225 Duesseldorf, Germany. 3. Division of Pediatrics III, University Children's Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany. 4. Division of Experimental Hematology & Cancer Biology, Cincinnati Children's Research Foundation, Cincinnati, OH 45229. 5. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229. 6. Department of Pediatrics, College of Medicine, King Saud University, Riyadh, 11211, Saudi Arabia. 7. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202. 8. Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia. 9. Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Abstract
BACKGROUND: Fanconi anaemia (FA) is a heterogeneous inherited disorder clinically characterised by progressive bone marrow failure, congenital anomalies and a predisposition to malignancies. OBJECTIVE: Determine, based on correction of cellular phenotypes, whether XRCC2 is a FA gene. METHODS: Cells (900677A) from a previously identified patient with biallelic mutation of XRCC2, among other mutations, were genetically complemented with wild-type XRCC2. RESULTS: Wild-type XRCC2 corrects each of three phenotypes characteristic of FA cells, all related to the repair of DNA interstrand crosslinks, including increased sensitivity to mitomycin C (MMC), chromosome breakage and G2-M accumulation in the cell cycle. Further, the p.R215X mutant of XRCC2, which is harboured by the patient, is unstable. This provides an explanation for the pathogenesis of this mutant, as does the fact that 900677A cells have reduced levels of other proteins in the XRCC2-RAD51B-C-D complex. Also, FANCD2 monoubiquitination and foci formation, but not assembly of RAD51 foci, are normal in 900677A cells. Thus, XRCC2 acts late in the FA-BRCA pathway as also suggested by hypersensitivity of 900677A cells to ionising radiation. These cells also share milder sensitivities towards olaparib and formaldehyde with certain other FA cells. CONCLUSIONS: XRCC2/FANCU is a FA gene, as is another RAD51 paralog gene, RAD51C/FANCO. Notably, similar to a subset of FA genes that act downstream of FANCD2, biallelic mutation of XRCC2/FANCU has not been associated with bone marrow failure. Taken together, our results yield important insights into phenotypes related to FA and its genetic origins. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND:Fanconi anaemia (FA) is a heterogeneous inherited disorder clinically characterised by progressive bone marrow failure, congenital anomalies and a predisposition to malignancies. OBJECTIVE: Determine, based on correction of cellular phenotypes, whether XRCC2 is a FA gene. METHODS: Cells (900677A) from a previously identified patient with biallelic mutation of XRCC2, among other mutations, were genetically complemented with wild-type XRCC2. RESULTS: Wild-type XRCC2 corrects each of three phenotypes characteristic of FA cells, all related to the repair of DNA interstrand crosslinks, including increased sensitivity to mitomycin C (MMC), chromosome breakage and G2-M accumulation in the cell cycle. Further, the p.R215X mutant of XRCC2, which is harboured by the patient, is unstable. This provides an explanation for the pathogenesis of this mutant, as does the fact that 900677A cells have reduced levels of other proteins in the XRCC2-RAD51B-C-D complex. Also, FANCD2 monoubiquitination and foci formation, but not assembly of RAD51 foci, are normal in 900677A cells. Thus, XRCC2 acts late in the FA-BRCA pathway as also suggested by hypersensitivity of 900677A cells to ionising radiation. These cells also share milder sensitivities towards olaparib and formaldehyde with certain other FA cells. CONCLUSIONS:XRCC2/FANCU is a FA gene, as is another RAD51 paralog gene, RAD51C/FANCO. Notably, similar to a subset of FA genes that act downstream of FANCD2, biallelic mutation of XRCC2/FANCU has not been associated with bone marrow failure. Taken together, our results yield important insights into phenotypes related to FA and its genetic origins. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
Breast cancer susceptibility; DNA interstrand crosslinks; Fanconi anemia; RAD51 paralogs; XRCC2
Authors: Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter Journal: Nat Genet Date: 2006-12-31 Impact factor: 38.330
Authors: D J Park; F Lesueur; T Nguyen-Dumont; M Pertesi; F Odefrey; F Hammet; S L Neuhausen; E M John; I L Andrulis; M B Terry; M Daly; S Buys; F Le Calvez-Kelm; A Lonie; B J Pope; H Tsimiklis; C Voegele; F M Hilbers; N Hoogerbrugge; A Barroso; A Osorio; G G Giles; P Devilee; J Benitez; J L Hopper; S V Tavtigian; D E Goldgar; M C Southey Journal: Am J Hum Genet Date: 2012-03-29 Impact factor: 11.025
Authors: Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg Journal: Nat Genet Date: 2010-04-18 Impact factor: 38.330
Authors: Najim Ameziane; Patrick May; Anneke Haitjema; Henri J van de Vrugt; Sari E van Rossum-Fikkert; Dejan Ristic; Gareth J Williams; Jesper Balk; Davy Rockx; Hong Li; Martin A Rooimans; Anneke B Oostra; Eunike Velleuer; Ralf Dietrich; Onno B Bleijerveld; A F Maarten Altelaar; Hanne Meijers-Heijboer; Hans Joenje; Gustavo Glusman; Jared Roach; Leroy Hood; David Galas; Claire Wyman; Rudi Balling; Johan den Dunnen; Johan P de Winter; Roland Kanaar; Richard Gelinas; Josephine C Dorsman Journal: Nat Commun Date: 2015-12-18 Impact factor: 14.919
Authors: Agata Smogorzewska; Shuhei Matsuoka; Patrizia Vinciguerra; E Robert McDonald; Kristen E Hurov; Ji Luo; Bryan A Ballif; Steven P Gygi; Kay Hofmann; Alan D D'Andrea; Stephen J Elledge Journal: Cell Date: 2007-04-05 Impact factor: 41.582
Authors: J-Y Park; T R Singh; N Nassar; F Zhang; M Freund; H Hanenberg; A R Meetei; P R Andreassen Journal: Oncogene Date: 2013-10-21 Impact factor: 9.867